Company profile: Akamis Bio
1.1 - Company Overview
Company description
- Provider of clinical-stage oncology therapeutics using its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to develop viral vector-based gene therapies that target solid tumors and express therapeutic proteins to stimulate an immune response. Offerings include NG-350A (secreted CD40 agonist monoclonal antibody expressed within tumors), clinical trials of T-SIGn® agents, and collaborations with academia, research institutes, and biopharma.
Products and services
- T-SIGn® therapeutics: Tumor-targeted, viral vector-based gene therapies that express therapeutic proteins inside solid tumors to stimulate immune responses
- NG-350A: Custom-engineered T-SIGn® therapeutic driving expression of a secreted CD40 agonist monoclonal antibody within tumors to activate immune cells
- Clinical Trials: Protocol-driven studies investigating efficacy of T-SIGn® therapeutics alone or combined with other immuno-oncology agents against solid tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Akamis Bio
Generation Bio
HQ: United States
Website
- Description: Provider of genetic medicines including iqDNA, a DNA construct designed to carry large or multiple genes to cells, potentially treating a wide range of diseases; ctLNP, a cell-targeted lipid nanoparticle delivery system for specific tissue targeting enabling personalized, redosable treatments; and RES, a rapid enzymatic synthesis process that efficiently produces highly pure DNA constructs, aiming for global access to genetic medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generation Bio company profile →
Tocagen
HQ: United States
Website
- Description: Provider of biopharmaceutical gene therapy products in development for the treatment of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tocagen company profile →
Foghorn Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapies leveraging its Gene Traffic Control platform to modulate the chromatin regulatory system, including FHD-286, an enzymatic BRG1/BRM inhibitor for AML and MDS; a selective BRM inhibitor and degrader for cancers with BRG1 mutations; and an ARID1B degrader for cancers with ARID1A mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foghorn Therapeutics company profile →
Laronde
HQ: United States
Website
- Description: Provider of an eRNA-based therapeutic platform, offering Endless RNA to program protein expression for therapeutic use; proprietary Natural NanoParticle technology to deliver biomolecules into human cells, enabling diverse administration routes and re-dosing; and AI-driven drug development using proprietary algorithms for rapid RNA medicine design.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Laronde company profile →
GenVec
HQ: United States
Website
- Description: Provider of differentiated, proprietary biopharmaceutical technologies for the creation of therapeutics and vaccines, developing and commercializing product candidates through collaborations with leading companies and organizations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenVec company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Akamis Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Akamis Bio
2.2 - Growth funds investing in similar companies to Akamis Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Akamis Bio
4.2 - Public trading comparable groups for Akamis Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →